About LL-37
LL-37 is the only human cathelicidin antimicrobial peptide and is widely used in immunology and innate-immunity research. Supplied as a lyophilized powder for laboratory investigations into innate immune signaling, host-defense pathway markers, and immunomodulatory mechanisms in controlled experimental models. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Assessment of Antimicrobial Activity of LL-37 Peptide Against Periapical Pathogens: A Cross-Sectional Study.
Recent research on LL-37: Assessment of Antimicrobial Activity of LL-37 Peptide Against Periapical Pathogens: A Cross-Sectional Study.
Read Full Study on PubMedAntimicrobial peptide WK-13-3D inhibits Japanese encephalitis virus infection by interacting with viral particles, potentially targeting the envelope protein.
Recent research on LL-37: Antimicrobial peptide WK-13-3D inhibits Japanese encephalitis virus infection by interacting with viral particles, potentially targeting the envelope protein.
Read Full Study on PubMedAdditional Studies
LL-37-Apo B(100) Complexes: Integrating Lipoprotein Biology and Innate Immunity in Atherogenesis and CAD Risk.
Recent research on LL-37: LL-37-Apo B(100) Complexes: Integrating Lipoprotein Biology and Innate Immunity in Atherogenesis and CAD Risk.
Read on PubMedHost antimicrobial peptide LL-37 inhibits CovS kinase activity and antagonizes CovR-Mediated activation in group A Streptococcus.
Recent research on LL-37: Host antimicrobial peptide LL-37 inhibits CovS kinase activity and antagonizes CovR-Mediated activation in group A Streptococcus.
Read on PubMedTargeting Drug-Resistant Tuberculosis with Antimicrobial Peptides: Opportunities and Challenges.
Recent research on LL-37: Targeting Drug-Resistant Tuberculosis with Antimicrobial Peptides: Opportunities and Challenges.
Read on PubMedLL-37-ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease.
Recent research on LL-37: LL-37-ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease.
Read on PubMedLipopolysaccharide-Phospholipid Separation in the Outer Membrane Vesicle Model Promotes Preferential Binding of Antimicrobial Peptides at Lipid Interfaces.
Recent research on LL-37: Lipopolysaccharide-Phospholipid Separation in the Outer Membrane Vesicle Model Promotes Preferential Binding of Antimicrobial Peptides at Lipid Interfaces.
Read on PubMedMolecular interaction modes of the host-defense peptide cathelicidin LL-37 and its mutants dictate diverse antimicrobial activities.
Recent research on LL-37: Molecular interaction modes of the host-defense peptide cathelicidin LL-37 and its mutants dictate diverse antimicrobial activities.
Read on PubMedRelated Research
Purchase LL-37 from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.